Advanced searches left 3/3

Chlorpropamide - Crossref

Summarized by Plex Scholar
Last Updated: 06 May 2022

* If you want to update the article please login/register

Improved Control of Non-insulin-dependent Diabetes Mellitus by Combined Halofenate and Chlorpropamide Therapy

For 48 wk or longer, four children were given 500–1000 mg halofenate every day. During the fourth month, the mean fasting glucose dropped from 227 27 to 107 19 mg/dl in the halofenate group, although placebo groups saw a decline from 242 22 to 208 29 mg/dl. P 0. 05; 9. 94 0. 68 mM and 7. 89 0. 44 mM) when halofenate was the only therapy when it was used as the only therapy.

Source link: https://doi.org/10.2337/diacare.7.1.19


Medication Compliance in Non-insulin-dependent Diabetes: A Randomized Comparison of Chlorpropamide and Insulin

Patients with diabetes may have a problem when it comes to medication administration. Patients with non-insulin-dependent diabetes are first treated with oral sulfonylureas because they fear greater compliance with insulin therapy. We compared insulin and chlorpropamide use in patients who are first prescribed NIDDM medications. Despite diet therapy, seventy-seven adults with hyperglycemia were randomly assigned to chlorpropamide or insulin. However, treatment pleasure with chlorpropamide was higher with chlorpropamide, and most patients preferred chlorpropamide to insulin.

Source link: https://doi.org/10.2337/diacare.8.3.219


The Long-term Effects of Chlorpropamide on Insulin, C-Peptide, and Proinsulin Secretion

It had been predicted that blood glucose lowering by sulfonylureas in non-insulin-dependent diabetes long-term was not due to a steady rise in insulin secretion. Thirteen nonobese NIDD patients who were not on diet alone were randomly tested on chlorpropamide therapy for more than three months. Insulin secretion increases for at least for over 1 yr chlorpropamide raises, according to the authors.

Source link: https://doi.org/10.2337/diacare.5.4.427


Insulin Responses to Glucose in Non-insulin-dependent Diabetic Subjects With and Without the Chlorpropamide-Alcohol Flush: Effect of Salicylate and Naloxone

We investigated the role of endogenous opiates and/or prostaglandins on some non-insulin-dependent diabetic subjects. A group of chlorpropamide-alcohol flush positive and a group of flush negative non-insulin dependent subjects were compared before and after intravenous glucose tolerance testing after and after sodium salicylate infusion, as well as before and after naloxone infusion.

Source link: https://doi.org/10.2337/diacare.5.4.404


Comparison of Chlorpropamide and Glibenclamide Treatment of Maturity-onset Diabetes: Control Assessed by Fasting Plasma Glucose Concentrations

In a crossover design analysis, twelve maturity-onset diabetic subjects were treated with chlorpropamide once daily, glibenclamide once daily, or glibenclamide twice daily. When given twice daily, there was no difference between the plasma glucose and insulin responses to chlorpropamide or glibenclamide. When glibenclamide was administered once a day, similar plasma glucose levels were obtained during the day, with marginally elevated plasma glucose levels during the night.

Source link: https://doi.org/10.2337/diacare.4.2.293


The Significance of the Cerebrospinal Fluid Examination in the Management of Chlorpropamide-induced Hypoglycemia

Since the reduction of low glucose levels in the cerebrospinal fluid just hours after its initial correction in the serum, investigating and monitoring the cerebrospinal fluid glucose levels in patients with chlorpropamide-induced neuroglycopenia will help physicians diagnose and treat more patients. In the presence of any atypical encephalopathy, primarily in the elderly diabetic patient treated with chlorpropamide and suffering from inadequate cerebral, hepatic, or renal function, a high degree of suspicion should exist.

Source link: https://doi.org/10.2337/diacare.3.2.248


Chlorpropamide Raises Fructose-2,6-Bisphosphate Concentration and Inhibits Gluconeogenesis in Isolated Rat Hepatocytes

The addition of chlorpropamide to hepatocytes isolated from fed rats raised the cellular concentration of fructose-2,6-bisphosphate, a key metabolite that plays a vital role in the regulation of hepatic glucose metabolism. Chlorpropamide's effect was dose dependent; a statistically significant rise was already present at 0. 2 mM of the sulfonylurea. The simultaneous action of these two agents on glucagon-treated hepatocytes appears to be closely linked to the synergistic accumulation of F-2,6-P2provoked.

Source link: https://doi.org/10.2337/diab.35.1.89


Potentiation of Hypoglycemic Effect of Chlorpropamide and Phenformin by Halofenate

paraphrasedl. After 80 days of halofenate therapy, the mean fasting plasma glucose for the five patients was 63 mg. /dl. The fasting plasma glucose levels returned to prehalofenate levels as oral diabetes was reduced. We did not find an effect of halofenate on diabetic patients treated with insulin or on the fasting plasma glucose levels of diabetic patients treated with diet alone in this research.

Source link: https://doi.org/10.2337/diab.26.4.291


Increase of Plasma Acetaldehyde: An Objective Indicator of the Chlorpropamide Alcohol Flush

During a CPAF challenge test, the rise of plasma acetaldehyde during the flush in 13 CPAF positive diabetics was noticeably higher than in 13 CPAF negative diabetics. In three CPAF-positive diabetics who were not exposed to alcohol without premedication with chlorpropamide, they were reduced to the level of CPAF negative diabetics, but not flushed. Acetaldehyde testing is an objective way to determine the chlorpropamide alcohol flush, and it is superior to skin temperature measurement.

Source link: https://doi.org/10.2337/diab.30.9.788


Beta Cell Function During Insulin or Chlorpropamide Treatment of Maturity-onset Diabetes Mellitus

Patients with Maturity-onset diabetic syndrome often have elevated overnight fasting plasma glucose levels associated with "normal" basal plasma insulin levels. If normal fasting plasma glucose levels are reached with insulin, Basal insulin or C-peptide levels will be sub-normal. A logical approach to maturity-onset diabetes is to provide basal normoglycemia by way of a recurring basal insulin supplement, which can be supplied by ultralente Insulin. When basal normoglycemia is established, the reduced insulin response of diabetics to intravenous glucose is marginally increased, suggesting that the elevated plasma glucose levels affect beta cell function. Mild hyperglycemia is not related to the insulin response to meals in a mild diabetic, but it can be depleted if gross hyperglycemia occurs. Basal normoglycemia can be obtained by "resting" beta cells or by stimulating them with sulfonylurea therapy.

Source link: https://doi.org/10.2337/diab.27.1.s241

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

Source Recommendations

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions